Application of 21725-69-9, In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 21725-69-9, name is Benzo[d]isoxazol-3-ol, introducing its new discovery.
MUSCARINIC AGONISTS
Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
One of the oldest and most widely used commercial enzyme inhibitors is aspirin, Application of 21725-69-9, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about Application of 21725-69-9
Reference£º
Benzisoxazole – Wikipedia,
Benzisoxazole – an overview | ScienceDirect Topics